Survey on Natural Radiosensitizing Agents Since 2000

Abstract

Key words: radiosensitizing agent, radiosensitizing agent, natural products, natural products, radiotherapy, radiotherapy, tumor, tumor, cancer, cancer, carcinoma, carcinoma

CLC Number:

R971.1

Supporting:

LU Jia, SHAO Hong^* . Survey on Natural Radiosensitizing Agents Since 2000[J]. .

[1] Alberola V, Cortesi E, Juan O. Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small celllung cancer [J]. Crit Rev Oncol Hematol, 2002, 44 Suppl: 31-41.
[2] Bell MC, Davidson SA, Mathis JM, et al. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I tria [J]. Gynecol Oncol, 2001, 80: 128-131.
[3] Calderoni A and Cerny T. Taxanes in lung cancer: a review with focus on the European experience [J]. Crit Revi Oncol Hematol, 2001, 38: 105-127.
[4] Cartee L, Davis C, Lin PS, et al. Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism [J]. Int J Radiat Biol, 2000, 76: 1323-1333.
[5] Chen Y, Pandya K, Keng PP, et al. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy [J]. Am J Clin Oncol, 2001, 24: 432-437.
[6] Crane CH, Janjan NA, Mason K, et al. Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies [J]. Oncology ( Huntingt), 2002, 16: 39-44.
[7] Ding ZJ, Su Y, Yin Q, et al. Observation of the close effect of radiotherapy combined with Antike on esophageal carcinoma [J]. Chin J Prev Treat, 2000, 7: 638-639.
[8] Dunton CJ, King SA, Neufeld J, et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer [J]. Gynecol Oncol, 2002, 85: 185-187.
[9] Fan MQ and Liu LP. Radiosensitizing effects of antike on nasopharyngeal carcinoma [J]. J North Chin Coal Med College, 2001, 3: 750-751.
[10] He HJ, He HF, Huang CJ, et al. The effect of radiosensitization of scorpion toxin [J]. Prac J Med Pharm, 2002, 19: 129-131.
[11] Hu GQ, Yuan XL, Hu CY. Clinical observation of Antike combined with radiotherapy on nasopharyngeal carcinoma [J]. Chin J Clin Oncol, 2002, 29: 440-441.
[12] Huober JB, Nakamura S, Meyn R, et al. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1127-1137.
[13] KimJS, Amorino GP, Pyo H, et al. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells [J]. Int J Radiat Oncol Biol Phys, 2001, 51: 525-534.
[14] Kohara H, Tabata M, Kiura K, et al. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line [J]. Clin Cancer Res, 2002, 8: 287-292.
[15] Langer CJ, Ruffer J, Rhodes H, et al. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme [J]. Int J Radiat Oncol Biol Phys,2001, 51: 113-119.
[16] Li XY, Wang Y, Yu LH, et al. Treatment of esophageal carcinoma with irisquinones combined radiotherapy [J]. Chin J Clin Oncol, 2000, 5: 272-274.
[17] Li AA, Lin YZ, Hu YH. Clinical observation of irisquinones combined with radiotherapy on esophageal carcinoma [J]. Chin J Clin Oncol Rehab, 2001, 8: 20.
[18] Li Q, Xie YH, Sun J Y, et al. Mechanism of radiosensitizing effect of Andi [J]. West Chin J Pharm Sci, 2003, 18: 6-9.
[19] Lin HM, Zhu SF, Chen ZH. Effect analysis of combined irisquinone and radiotherapy for middle and late stage nasopharyngeal cancer [J]. Chin J Clin Oncol, 2001, 28: 439-440.
[20] Liu LH and Yang XF. Effects of irisquinone combined with radiotherapy on esophageal cancers of 112 patients [J]. Acta Med Sin, 2000, 13: 467-468.
[21] Liu XQ, Hao JF, Zhai LM, et al. The study on late course accelerated hyperfraction radiotherapy in combination with Anka in nasopharyngeal carcinoma. [J] Chin J Cancer Prev Treat, 2000, 7: 469-472.
[22] Liu J. New advancement of pacitaxel combined radiotherapy in head and neck cancers [J]. Foreign Med Sci (Otorhinolaryng), 2002, 26: 5-7.
[23] Mao XW, Green LM, Gridley DS. Evaluation of polysaccharopeptide effects against C6 glioma in combination with radiation [J]. Oncology, 2001, 61: 243-253.
[24] Ning C and Xu F. Observation of 30 patients with niddle and later stage lung cancers treated with irisquinone combined radiotherapy [J]. J Pract Trad Chin Med, 2000, 16: 7.
[25] Pond-Tor S, Rhodes RG, Dahlberg PE, et al. Enhancement of radiosensitivity of the MCF-7 breast cancer cell line with human chorionic gonadotropin [J]. Breast Cancer Res Treat, 2002, 72: 45-51.
[26] Pradier O, Rave-Frank M, Lehmann J, et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ) [J]. Int J Cancer, 2001, 91: 840-845.
[27] Qi C, Han QC, He HJ, et al. Study on radiosensitization and thermosensitization of scorpion toxin [J]. J Postgrad Med, 2000, 23: 30-32.
[28] Qi WQ, Qiao DH, Martinez JD. Caffeine induces TP53-independent G(1)-phase arrest and apoptosis in human lung tumor cells in a dose-dependent manner [J]. Radiat Res,2002, 157: 166-174.
[29] Qu YQ, Dong LH, Li BY, et al. Present effects observing of Aidi Chinese herb plus radiotherapy for advanced esophageal cancer in aging [J]. Chin J Gerontol, 2001, 21: 33-34.
[30] Raitanen M, Rantanen V, Kulmala J, et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines [J]. Int J Cancer, 2002, 97: 853-857.
[31] Ren ZY, Bai CX, Hong QY, et al. The radiosensitization of docetaxel on Lewis lung cancer in vivo [J]. J Radiat Res Radiat Process, 2002, 20: 191-196.
[32] Safran H, Wanebo HJ, Hesketh PJ, et al. Paclitaxel and concurrent radiation for gastric cancer [J]. Int J Radiat Oncol Biol Phys, 2000, 46: 889-894.
[33] Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer [J]. Int J Radiat Oncol Biol Phys, 2001, 49: 1275-1279.
[34] Schuck A, Muller SB, Kohler A, et al. Combined radiochemotherapy with paclitaxel in the treatment of malignant glioma [J]. Strahlenther Onkol, 2002, 178: 486-490.
[35] Shi YQ, Blattmann H, Crompton NE. Wortmannin selectively enhances radiation-induced apoptosis in proliferative but not quiescent cellsv [J]. Int J Radiat Oncol Biol Phys, 2001, 49: 421-425.
[36] Stuben G, Thews O, Pottgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice [J]. J Cancer Res Clin Oncol, 2001, 127: 346-350.
[37] Sun LF, Sun Y, Shen WJ, et al. Effect of the mixture of toad skin and Chinese angelic on radiosensitivity of renal cell lines and its mechanisms [J]. Chin J Clin Oncol Rehab, 2000, 7: 1-3.
[38] Talla M, MangoldM, Angellier E, et al. Acute cutaneous reactions induced by docetaxel: a case report [J]. Therapie,2001, 56: 632-633.
[39] Varterasian ML, Mohammod RM, Shurafa MS, et al. Phase II trail of bryostatin 1 in patients with relapsed low grade nonHodgkin’s lymphoma and chronic lymphocytic leukemia [J]. Clin Cancer Res, 2000, 6: 825.
[40] Wall NR, Mohammod RM, Reddy KB, et al. Bryostatin 1 induced ubiquitization and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line [J]. Int J Mol Med, 2000, 5: 165.
[41] Wu HGand Choy H. Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer [J]. Oncology ( Huntingt), 2002, 16: 13-18.
[42] Xu J, Chen ZH, Lin HR, et al. Radiotherapy combined with Antike for esophageal cancer [J]. Chin J Cancer Prev Treat, 2002, 9: 528-529.
[43] Zhou YQ and Bian XH. Clinical study on NPC radiosensitization of irisquinones [J]. Acta Univ Med Nanjing, 2001, 21: 328-330.

Survey on Natural Radiosensitizing Agents Since 2000

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gedi Zhang, Gengxin Liu, Ziyou Yan. Therapeutic efficacy evaluation and mechanism of action based on meta-analysis and network pharmacology of Li Chong Decoction (Bolus) for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 720-735.
[2]	Haoxin Du, Qi Bao, Huangqianyu Li, Yichen Zhang, Haishaerjiang Wushouer, Luwen Shi, Xiaodong Guan. Health status of middle-aged and elderly cancer survivors in China [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 744-754.
[3]	Wentao Zhu, Wanglong Hong, Miaomiao Zheng, Guoqiang Ma, Aizong Shen. Combination of pembrolizumab and chemotherapy as first-line treatment in advanced triple-negative breast cancer: a cost-effectiveness analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 587-597.
[4]	Yancong Zhao, Huiyuan Gong, Jinghua Li. Overexpression of hBD3 inhibits cell proliferation, cell cycle, and migration in colon cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 250-259.
[5]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[6]	Yuqian Zhang, Haiying Niu, Yiran Jin. Network pharmacology-based strategy to investigate anticancer mechanisms of Catharanthus roseus (L.) G. Don [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 911-922.
[7]	Kai Li, Bingjie Tang, Xinlong Chai, Yang Ping, Lihong Wang, Jin Su. Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 773-795.
[8]	Ning Ding, Tao Zhang, Ji Luo, Haochen Liu, Yu Deng, Yongheng He. Study on the mechanism of Baishao Qiwu Decoction in the treatment of colorectal cancer based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(1): 17-31.
[9]	Neha Dangi, Shikha Sharma. Cancer chemotherapy with novel bioactive natural products [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 589-607.
[10]	Ipargul Hafiz, Zhaozhi Wang, Hongji He, Zhezhe Li, Mei Wang. Exploring the mechanism of Peganum harmala L. seeds on hepatocellular carcinoma based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(7): 517-529.
[11]	Weiping Zhao, Qi Ge, Zijun Ding, Leizhi Pan, Ziqing Gu, Yang Liu, Hua Cai. Network pharmacology and metabolomics-based detection of the potential pharmacological effects of the active components in Chrysanthemum morifolium 'Chuju' [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 412-428.
[12]	Jianwei Dong, Xuejiao Li, Chen Yang, Yanqing Zhang, Huifang Zhou, Yali Li. The antioxidant activity and total phenolic and total flavonoid contents of Pyracantha fortuneana fruit can be improved by solid-state fermentation with Rhizopus oryzae and Penicillium commune [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 452-460.
[13]	Liangyu Liu, Yuke Yang, Xiao Du, Tong Wu, Jiannong Wang. Three previously undescribed steroidal glycoalkaloids from Solanum lyratum and their anti-tumor activities [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 192-201.
[14]	Axi Shi, Tiantian Shen, Wenbin Xia, Lili Xi, Lijun Wang, Yuhui Wei. Icaritin enhances sorafenib-induced apoptosis through a mitochondria-dependent pathway [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 928-937.
[15]	Weiwei Jiang, Haiyan Quan, Lu He, Xing Jiang. The diagnostic and prognostic value of CCTs in human hepatocellular carcinoma: a study based on integrated bioinformatics [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 782-797.